Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding

Antiviral Therapy

Volumn 16, Issue 5, 2011, Pages 621-628

  Giles, Michelle ^a,b,c,d,e   Visvanathan, Kumar ^b,d   Sasadeusz, Joe ^a,e  

^a ALFRED HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; LAMIVUDINE; PLACEBO; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL THERAPY; BREAST FEEDING; DRUG BLOOD LEVEL; DRUG CARCINOGENICITY; DRUG EFFICACY; DRUG EXCRETION; DRUG MILK LEVEL; FETOTOXICITY; HEPATITIS B; HUMAN; INTRAUTERINE INFECTION; MATERNAL BLOOD; NONHUMAN; PLACENTAL TRANSFER; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; SINGLE DRUG DOSE; TERATOGENICITY; VIRUS TRANSMISSION;

ADENINE; ANTIVIRAL AGENTS; BREAST FEEDING; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; NUCLEOSIDES; PHOSPHONIC ACIDS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMIDINONES;

EID: 80052486957     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1813     Document Type: Review

References (61)

1. World Health Organization. Hepatitis B: fact sheet N° 204 (Updated August 2008. Accessed 7 October 2009.) Available from http://www.who.int/ mediacentre/factsheets/fs204/en/
2. Coursaget P., Yvonnet B., Chotard J., et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987; 22:1-5. (Pubitemid 17077593)
3. McMahon B.J., Alward W.L., Hall D.B., et al. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151:599-603. (Pubitemid 15102154)
4. Xu W.M., Cui Y.T., Wang L., et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, doubleblind, placebo-controlled study. J Viral Hepat 2009; 16:94-103.
5. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-972. (Pubitemid 41191673)
6. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119:312-323. (Pubitemid 23319890)
7. Cooksley W.G.E., Piratvisuth R., Lee S-D, et al. Peginterferon alfa-2a (40kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305. (Pubitemid 36801917)
8. Janssen H.L.A., Senturk H., Zeuzem S., et al. Peginterferon alfa-2b and lamivudine combination therapy compared with peginterferon alfa-2b for chronic HBeAg positive hepatitis B: a randomized trial in 307 patients. Hepatology 2003; 38 Suppl 1:246A.
9. Buster E.H., Flink H.J., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow up of HBeAgpositive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135:459-467.
10. Pons J.C., Lebon P., Frydman R., Delfraissy J.F. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 1995; 10:7-10.
11. Evans A.T., Carandang G., Quilligan E.J., Cesario T.C. Interferon responses in maternal and fetal mice. Am J Obstet Gynecol 1985; 152:99-102. (Pubitemid 15039820)
12. Haggstrom J., Adriansson M., Hybbinette T., Harnby E., Thorbert G. Two cases of CML treated with alphainterferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum. Eur J Haematol 1996; 57:101-102. (Pubitemid 26241817)
13. Kumar A.R., Hale T.W., Mock R.E. Transfer of interferon alfa into human breast milk. J Hum Lact 2000; 16:226-228.
14. Baer M.R. Normal full-term pregnancy in a patient with chronic myelogenous leukemia treated with alphainterferon. Am J Hematol 1991; 37:66.
15. Milano V., Gabrielli S., Rizzo N., et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. J Matern Fetal Med 1996; 5:74-78.
16. Mancuso A., Ardita F.V., Leonardi J., Scuderi M. Interferon alpha-2a therapy and pregnancy. Report of a case of chronic inflammatory demyelinating polyneuropathy. Acta Obstet Gynecol Scand 1998; 77:869-870. (Pubitemid 28410109)
17. Trotter J.F., Zygmunt A.J. Conception and pregnancy during interferon-alpha therapy for chronic hepatitis C. J Clin Gastroenterol 2001; 32:76-78. (Pubitemid 32038117)
18. Hiratsuka M., Minakami H., Koshizuka S., Sato I. Administration of interferon-alpha during pregnancy: Effects on fetus. J Perinat Med 2000; 28:372-376. (Pubitemid 32952978)
19. Labarga P., Pinilla J., Cachorro I., Ruiz Y. Infant of 22 months of age with no anomalies born from a HCV-and HIV-infected mother under treatment with pegylated interferon, ribavirin and antiretroviral therapy during the first 16 weeks of pregnancy. Reprod Toxicol 2007; 24:414-416. [Erratum in Reprod Toxicol 2008; 26:310]. (Pubitemid 350016765)
20. Giles M.L., Audsley J., Lewin S.R. Lamivudine. In Grayson L, Crowe, S, Mills J et al. (Editors). Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 6th Ed. London, Hodder Arnold 2010; pp. 2545-2562.
21. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68. (Pubitemid 28304879)
22. Liaw Y.F., Sung J.J.Y., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
23. Lok A.S., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722. (Pubitemid 37500436)
24. Bloom S.L., Dias K.M., Bawdon R.E., Gilstrap L.C., III. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol 1997; 176:291-293. (Pubitemid 27107911)
25. Mandelbrot L., Peytavin G., Firtion G., Farinotti R. Maternalfetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am J Obstet Gynecol 2001; 184:153-158. (Pubitemid 32141658)
26. 3TC (lamivudine). Product information 2010. GlaxoSmithKline, Boronia, Victoria, Australia.
27. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry international report for1 January 1989 through 31 July 2010. Wilmington, NC: Registry Coordinating Center; 2010. (Updated December2010. Accessed 27 April 2011.) Available from www. apregistry.com/forms/interim- report.pdf
28. Van Nunen A.B., De Man R.A., Heijtink R.A., Neisters H.G., Schalm S.W. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000; 32:1040-1041. (Pubitemid 30368101)
29. Kazim S.N., Wakil S.M., Khan L.A., Hasnain S.E., Sarin S.K. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002; 359:1488-1489. (Pubitemid 34457770)
30. Van Zonneveld M., Van Nunen A.B., Niesters H.G., De Man R.A., Schalm S.W., Janssen H.L. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10:294-297. (Pubitemid 36801916)
31. Shapiro R.L., Holland D.T., Capparelli E., et al. Antiretroviral concentrations in breastfeeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-727. (Pubitemid 41193069)
32. Moodley J., Moodley D., Pillay K., et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178:1327-1333.
33. Mirochnick M., Thomas T., Capparelli E., et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53:1170-1176.
34. Benhammou V., Warszawski J., Bellec S., et al. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS 2008; 22:2165-2177.
35. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816. (Pubitemid 36245757)
36. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800-807. (Pubitemid 36245756)
37. Chen E.Q., Wang L.C., Lei J., Xu L., Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 2009; 6:163.
38. Hepsera® (adefovir dipivoxil). Product information version 3 2006. Gilead Sciences, Foster City, CA, USA.
39. Chang T.T., Gish R.G., De Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010. (Pubitemid 43357804)
40. Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
41. Chang T.T., Liaw Y.F., Wu S.S., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886-893.
42. Baraclude® (entecavir monohydrate). Product information 2010. Bristol-Myers Squibb. Princeton, NJ, USA.
43. Viread (tenofovir disoproxil fumarate). Product information 2005. Gilead Sciences, Foster City, CA, USA.
44. Marcellin P., Heathcote E.J., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
45. Burchett S.K., Best B., Mirochnick M., et al. Tenofovir pharmacokinetics during pregnancy, at delivery and post partum. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 738b.
46. Bonora S., Gonzalez de Requena D., Chiesa E., et al. Transplacental passage of tenofovir (TDF) and other antiretrovirals (ARVs) at delivery. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 738a.
47. Tarantal A.F., Castillo A., Ekert J.E., Bischofberger N., Martin R.B. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29:207-220. (Pubitemid 34208529)
48. Van Rompay K.K.A., Durand-Gasselin L., Brignolo L.L., et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144-3160.
49. Haberl A., Linde R., Reitter A., et al. Safety and efficacy of tenofovir in pregnant women. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 627a.
50. Nurutdinova D., Onen N.F., Hayes E., Mondy K., Overton E.T. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 2008; 42:1581-1585.
51. Chidziva E., Zwalango E., Russell E., et al. Outcomes in infants born to HIV-infected mothers receiving long-term ART in the DART trial, 2004-2009. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 924.
52. Linde R., Konigs C., Rusicke E., Haberl A., Reitter A., Kreuz W. Tenofovir therapy during pregnancy does not affet renal function in HIV-exposed children. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 925.
53. + mothers.17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 926.
54. Purdy J.B., Gafni R.I., Reynolds J.C., Zeichner S., Hazra R. Decreased bone mineral density with off-label use of tenofovir in HIV-infected children and adolescents. J Pediatr 2008; 152:582-584. (Pubitemid 351381047)
55. Gafni R.I., Hazra R., Reynolds J.C., et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-e718. (Pubitemid 46089998)
56. Kim J.W., Park S.H., Louie S.G. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother 2006; 40:472-478.
57. But D.Y., Yuen M., Fung J., Lai C.L. Safety evaluation of telbivudine. Expert Opin Drug Saf 2010; 9:821-829.
58. Lai C.L., Gane E., Liaw Y.F., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588. (Pubitemid 350294224)
59. Liaw Y.F., Gane E., Leung N., et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486-495.
60. Han G., Zhao W., Jiang H., et al. A study of the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Hepatol Int 2010; 4:58.
61. Bridges E.G., Selden J.R., Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother 2008; 52:2521-2528. (Pubitemid 351915684)